Universitaetsklinikum Koeln 50937 Koeln (Nordrhein-Westfalen) GermanyZurückgezogen» Google-MapsUniversitatsklinikum Leipzig 04103 Leipzig (Sachsen) GermanyRekrutierend» Google-MapsUniversitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, 72076 Tübingen (Baden-Württemberg) GermanyRekrutierend» Google-MapsOnkologisches Zentrum Universitätsklinikum Würzburg Josef-Schneider-Straße 6 97080 Würzburg DeutschlandRekrutierend» Google-MapsUniversity of Alabama at Birmingham 35294 Birmingham United StatesRekrutierend» Google-MapsMayo Clinic Cancer Center-Scottsdale 85054 Phoenix United StatesZurückgezogen» Google-MapsCity of Hope 91010 Duarte United StatesRekrutierend» Google-MapsUniversity of California, San Francisco 94143 San Francisco United StatesRekrutierend» Google-MapsStanford University Medical Center 94305-5623 Stanford United StatesRekrutierend» Google-MapsYale University 06510 New Haven United StatesZurückgezogen» Google-MapsMayo Clinic in Florida 32224 Jacksonville United StatesZurückgezogen» Google-MapsWinship Cancer Institute Emory University 30322 Atlanta United StatesRekrutierend» Google-MapsUniversity of Kansas 66205 Westwood United StatesZurückgezogen» Google-MapsDana-Farber Cancer Institute 02215-5418 Boston United StatesZurückgezogen» Google-MapsUniversity of Michigan Comprehensive Cancer Center 48109 Ann Arbor United StatesZurückgezogen» Google-MapsBarbara Ann Karmanos Cancer Institute 48201 Detroit United StatesRekrutierend» Google-MapsHackensack University Medical Center 07601 Hackensack United StatesZurückgezogen» Google-MapsIcahn School of Medicine at Mount Sinai 10029 New York United StatesRekrutierend» Google-MapsMemorial Sloan-Kettering Cancer Center 10065 New York United StatesRekrutierend» Google-MapsMayo Clinic Cancer Center 55905 Rochester United StatesZurückgezogen» Google-MapsLevine Cancer Institute 28204 Charlotte United StatesRekrutierend» Google-MapsDuke University Medical Center 27710 Durham United StatesZurückgezogen» Google-MapsThe Ohio State University Wexner Medical Center - James Cancer Hospital 43210 Columbus United StatesZurückgezogen» Google-MapsUniversity of Pennsylvania 19104 Philadelphia United StatesRekrutierend» Google-MapsUniversity of Pittsburgh Medical Center 15232 Pittsburgh United StatesZurückgezogen» Google-MapsVanderbilt - Ingram Cancer Center 37212 Nashville United StatesZurückgezogen» Google-MapsUniversity of Texas Southwestern Medical Center 75390 Dallas United StatesZurückgezogen» Google-MapsHuntsman Cancer Institute 84112 Salt Lake City United StatesZurückgezogen» Google-MapsFred Hutchinson Cancer Research Center 98109 Seattle United StatesZurückgezogen» Google-MapsMedical College Of Wisconsin 53226 Milwaukee United StatesZurückgezogen» Google-MapsUniversitair Ziekenhuis Gent - UZ GENT 9000 Gent BelgiumRekrutierend» Google-MapsUniversitaire Ziekenhuizen Leuven 3000 Leuven BelgiumRekrutierend» Google-MapsTom Baker Cancer Centre T2N 4N2 Calgary CanadaRekrutierend» Google-MapsCross Cancer Institute T6G 1Z2 Edmonton CanadaRekrutierend» Google-MapsUniversity Health Network (UHN) Princess Margaret Cancer Centre M5G 2M9 Toronto CanadaRekrutierend» Google-MapsMcGill University Health Centre H4A 3J1 Montreal CanadaRekrutierend» Google-MapsCentre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez 59000 Lille Cedex FranceRekrutierend» Google-MapsC.H.U. Hotel Dieu - France 44093 Nantes FranceRekrutierend» Google-MapsCentre Hospitalier Lyon Sud 69495 Pierre Benite FranceRekrutierend» Google-MapsCHRU Hôpital Jean Bernard 86021 Poitiers FranceRekrutierend» Google-MapsPôle IUC Oncopole CHU 31059 Toulouse cedex 9 FranceRekrutierend» Google-MapsCHRU Hôpital Bretonneau 37044 Tours FranceRekrutierend» Google-MapsAzienda Ospedaliera Papa Giovanni XXIII 24127 Bergamo ItalyRekrutierend» Google-MapsIstituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi 40138 Bologna ItalyRekrutierend» Google-MapsFondazione IRCCS Istituto Nazionale dei Tumori 20133 Milano ItalyRekrutierend» Google-MapsA.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette 10126 Turin ItalyZurückgezogen» Google-MapsVU Medisch Centrum 1081 HV Amsterdam NetherlandsRekrutierend» Google-MapsUniversitair Medisch Centrum Groningen 9713 GZ Groningen NetherlandsZurückgezogen» Google-MapsErasmus MC 3075 EA Rotterdam NetherlandsZurückgezogen» Google-MapsHosp. Univ. Germans Trias I Pujol 08916 Badalona SpainRekrutierend» Google-MapsHosp. Clinic I Provincial de Barcelona 08036 Barcelona SpainRekrutierend» Google-MapsHosp. Univ. 12 de Octubre 28041 Madrid SpainRekrutierend» Google-MapsClinica Univ. de Navarra 31008 Pamplona SpainRekrutierend» Google-MapsHosp. Quiron Madrid Pozuelo 28223 Pozuelo de Alarcon SpainRekrutierend» Google-MapsHosp. Clinico Univ. de Salamanca 37007 Salamanca SpainRekrutierend» Google-MapsHosp. Univ. Marques de Valdecilla 39008 Santander SpainRekrutierend» Google-MapsSahlgrenska University Hospital 413 45 Göteborg SwedenRekrutierend» Google-MapsSkane University Hospital 221 85 Lund SwedenRekrutierend» Google-MapsHaematology Centre, R 51 SE-141 86 Stockholm SwedenRekrutierend» Google-MapsUniversity College Hospital NW1 2PG London United KingdomRekrutierend» Google-MapsUniversity Hospital Southampton SO16 6YD Sothampton United KingdomRekrutierend» Google-MapsRoyal Marsden Hospital SM2 5PT Sutton United KingdomRekrutierend» Google-Maps
1. Overall Response Rate (ORR) (Time Frame - Up to 2.9 years): ORR is defined as the proportion of participants who have a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria.
Secondary outcome:
1. Duration of Response (DOR) (Time Frame - Up to 2.9 years): DOR will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria, or death due to PD, whichever occurs first.
2. Very Good Partial Response (VGPR) or Better Rate (Time Frame - Up to 2.9 years): VGPR or better rate is defined as the percentage of patients who achieve a VGPR or better according to IMWG response criteria.
3. Complete Response (CR) or Better Rate (Time Frame - Up to 2.9 years): CR or better rate is defined as the percentage of patients who achieve a complete response (CR) or better according to IMWG response criteria.
4. Stringent Complete Response (sCR) Rate (Time Frame - Up to 2.9 years): sCR rate is defined as the percentage of patients who achieve a stringent complete response (sCR) according to IMWG response criteria.
5. Time to Response (TTR) (Time Frame - Up to 2.9 years): TTR is defined as the time between date of first dose of study drug and the first efficacy evaluation that the participant has met all criteria for PR or better.
6. Progression-free Survival (PFS) (Time Frame - Up to 2.9 years): PFS is defined as the time from the date of first dose of study drug to the date of first documented disease progression, as defined in the IMWG criteria, or death due to any cause, whichever occurs first.
7. Overall Survival (OS) (Time Frame - Up to 2.9 years): OS is defined as the time from the date of first dose of study drug to the date of the participant's death.
8. Minimal Residual Disease (MRD) Negative Rate (Time Frame - Up to 2.9 years): MRD-negative rate is defined as the proportion of participants who achieved MRD-negative status to a threshold of 10^-5 at any timepoint after initial dose of teclistamab and before disease progression or starting subsequent therapy
9. Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability (Time Frame - Up to 2.9 years): An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
10. Number of Participants with Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability (Time Frame - Up to 2.9 years): An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
11. Number of Participants with AEs by Severity (Time Frame - Up to 2.9 years): Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.
12. Number of Participants with Laboratory Abnormalities in Clinical Laboratory Values (Time Frame - Up to 2.9 years): Number of participants with laboratory abnormalities in clinical laboratory values (such as hemoglobin, platelets) will be reported.
13. Serum Concentration of Teclistamab (Time Frame - Up to 3 months): Serum concentrations of teclistamab will be reported.
14. Number of Participants with Teclistamab Antibodies (Time Frame - Up to 2.9 years): Antibodies to teclistamab will be assessed to evaluate potential immunogenicity.
15. Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC QLQ-C30) (Time Frame - Baseline, up to 2.9 years): The EORTC- QLQ-Core-30 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The recall period is 1 week ("past week") and responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms.
16. Change from Baseline in HRQoL as Assessed by EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) (Time Frame - Baseline, up to 2.9 years): The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The scores for the 5 separate questions are categorical and cannot be analyzed as cardinal numbers.
17. Change from Baseline in HRQoL as Assessed by Patient Global Impression of Severity (PGIS) (Time Frame - Baseline, up to 2.9 years): The PGIS is a single item that assesses severity of the participant's health state, on a 5-point verbal rating scale. Score ranges from 1 (None) to 5 (Very Severe).
18. Overall Response Rate (ORR) in Participants with High-risk Molecular Features (Time Frame - Up to 2.9 years): ORR in participants with high risk is defined as the overall response rate among the high risk molecular subgroups (del17p, t(4;14), t(14;16), or other high-risk molecular subtypes).
